Roche's divarasib beat Amgen's Lumakras and Bristol Myers Squibb's Krazati in a head-to-head Phase 3 trial for KRAS G12C non-small cell lung cancer, showing statistically significant improvements in p…
Revolution Medicines presented complete Phase 3 data for daraxonrasib at ASCO 2026, showing the drug cut the risk of death by 60% and nearly doubled median overall survival to 13.2 months versus 6.7 m…
Eli Lilly reported positive interim Phase 1b data for its in vivo PCSK9 base editor VERVE-102, showing single-dose LDL-C reductions of up to 62% sustained for 18 months in patients with heterozygous f…
Twenty-seven strategic partnerships between frontier AI labs and major pharmaceutical companies have been tracked as of May 2026, with Anthropic's Claude leading at 52% of deals, followed by OpenAI at…
Cytokinetics’ aficamten met both primary and secondary endpoints in a Phase 3 trial for non-obstructive hypertrophic cardiomyopathy, positioning the drug for a potential regulatory filing and setting …
A new prediction market called Endpoint Arena allows users to place real-money wagers on whether specific clinical trial outcomes will occur, including bets on cancer drug efficacy. The platform, whic…